​

Bio-Techne (TECH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TECH Stock Forecast

Bio-Techne (TECH) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $69.33, with a high of $79.00 and a low of $62.00. This represents a 34.70% increase from the last price of $51.47.

$50 $57 $64 $71 $78 $85 High: $79 Avg: $69.33 Low: $62 Last Closed Price: $51.47

TECH Stock Rating

Bio-Techne stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (72.00%), 7 Hold (28.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 7 18 0 Strong Sell Sell Hold Buy Strong Buy

TECH Price Target Upside V Benchmarks

TypeNameUpside
StockBio-Techne34.70%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-49
Avg Price Target-$69.00$70.22
Last Closing Price$51.47$51.47$51.47
Upside/Downside-34.06%36.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 261104--15
Feb, 26-105--15
Jan, 261113--15
Dec, 251113--15
Nov, 25-114--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 05, 2026Stifel Nicolaus$65.00$67.64-3.90%26.29%
Feb 05, 2026UBS$79.00$68.6715.04%53.49%
Feb 05, 2026Robert W. Baird$70.00$68.671.94%36.00%
Jan 05, 2026Evercore ISI$62.00$59.653.94%20.46%
Dec 12, 2025Justin BowersDeutsche Bank$72.00$59.6720.66%39.89%
Nov 20, 2025Argus Research$68.00$58.6415.96%32.12%
Nov 06, 2025Evercore ISI$68.00$58.4016.44%32.12%
Sep 02, 2025Conor McNamaraRBC Capital$73.00$53.4236.65%41.83%
Mar 17, 2025Evercore ISI$75.00$62.5819.85%45.72%
Oct 31, 2024Catherine SchulteRobert W. Baird$84.00$76.0210.50%63.20%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 05, 2026Cowen & Co.BuyBuyhold
Feb 05, 2026UBSBuyBuyhold
Feb 04, 2026CitigroupBuyBuyhold
Feb 03, 2026BenchmarkBuyBuyhold
Dec 12, 2025Deutsche BankBuyBuyhold
Oct 14, 2025Cowen & Co.BuyBuyhold
Sep 02, 2025RBC CapitalSector PerformOutperformupgrade
Oct 30, 2024KeyBancOverweightOverweighthold
Aug 16, 2024ScotiabankSector OutperformSector Outperformhold
Aug 13, 2024RBC CapitalSector PerformSector Performhold

Financial Forecast

EPS Forecast

Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$0.91$1.73$1.81$1.07----
Avg Forecast$1.64$1.98$2.00$1.78$1.88$2.18$2.49-
High Forecast$1.66$2.01$2.05$1.80$1.92$2.35$2.80-
Low Forecast$1.61$1.94$1.96$1.76$1.83$2.04$2.28-
Surprise %-44.51%-12.63%-9.50%-39.89%----

Revenue Forecast

$900M $1B $1B $2B $2B $2B Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$931.03M$1.11B$1.14B$1.16B----
Avg Forecast$924.08M$1.10B$1.14B$1.16B$1.22B$1.33B$1.48B$1.86B
High Forecast$934.77M$1.12B$1.16B$1.18B$1.23B$1.36B$1.48B$1.89B
Low Forecast$909.11M$1.09B$1.12B$1.14B$1.21B$1.31B$1.47B$1.83B
Surprise %0.75%0.05%-0.54%0.02%----

Net Income Forecast

Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28
Reported$140.41M$272.05M$285.26M$168.10M----
Avg Forecast$128.87M$196.47M$321.71M$150.68M$300.71M$352.85M$408.30M-
High Forecast$154.64M$235.76M$329.07M$180.82M$308.01M$377.54M$450.83M-
Low Forecast$103.09M$157.18M$315.03M$120.54M$293.42M$328.15M$365.77M-
Surprise %8.96%38.47%-11.33%11.56%----

TECH Forecast FAQ

Is Bio-Techne stock a buy?

Bio-Techne stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bio-Techne is a favorable investment for most analysts.

What is Bio-Techne's price target?

Bio-Techne's price target, set by 25 Wall Street analysts, averages $69.33 over the next 12 months. The price target range spans from $62 at the low end to $79 at the high end, suggesting a potential 34.70% change from the previous closing price of $51.47.

How does Bio-Techne stock forecast compare to its benchmarks?

Bio-Techne's stock forecast shows a 34.70% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Bio-Techne over the past three months?

  • March 2026: 6.67% Strong Buy, 66.67% Buy, 26.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 6.67% Strong Buy, 73.33% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Bio-Techne’s EPS forecast?

Bio-Techne's average annual EPS forecast for its fiscal year ending in June 2025 is $1.88, marking a 75.70% increase from the reported $1.07 in 2024. Estimates for the following years are $2.18 in 2026, $2.49 in 2027, and $0 in 2028.

What is Bio-Techne’s revenue forecast?

Bio-Techne's average annual revenue forecast for its fiscal year ending in June 2025 is $1.22B, reflecting a 5.28% increase from the reported $1.16B in 2024. The forecast for 2026 is $1.33B, followed by $1.48B for 2027, and $1.86B for 2028.

What is Bio-Techne’s net income forecast?

Bio-Techne's net income forecast for the fiscal year ending in June 2025 stands at $300.71M, representing an 78.88% increase from the reported $168.1M in 2024. Projections indicate $352.85M in 2026, $408.3M in 2027, and $0 in 2028.